FindTrial
Sign In

Role of Nefopam in Rituximab Transfusion Reaction

Role of Nefopam in Rituximab Transfusion Reaction

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05648058
Enrollment
100
Registered
2022-12-13
Start date
2022-12-20
Completion date
2023-11-20
Last updated
2022-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nefopam

Brief summary

the patients will be taken nefopam ampule 50 mg before rituximab in the first group while the second group will be taken diphenhydramine ampule 10 mg before rituximab in the second group

Detailed description

the two groups will be taken standard therapy (hydrocortisone vial 100 mg and acetaminophen 1000 mg) 30 min before rituximab

Interventions

DRUGNefopam ampule

nefopam ampule 50 mg

DRUGdiphenhydramine ampule

diphenhydramine ampule 10 mg

Sponsors

Ministry Of Health / Nineveh Health Directorate
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 18 - 80 years old male and female will be taken rituximab

Exclusion criteria

* less than 18 years old more than 80 years old diabetic patients

Design outcomes

Primary

MeasureTime frameDescription
transfusion reaction30 minfever, riger, rash, chills, pruritus and bronchospasm

Contacts

Primary Contactfakhraldin marwan
drfakhralin@gmail.com07817639470
Backup Contactzainab thanon
zainabthanon@gmail.com07518097301

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026